WASHINGTON - Following the pace set by the Senate earlier this summer, a House subcommittee on Wednesday began looking at ways of stopping brand-name drug companies and generic drug manufacturers from "gaming" the system to keep the competition off the market. (Bioworld Today)

WASHINGTON - Following the pace set by the Senate earlier this summer, a House subcommittee on Wednesday began looking at ways of stopping brand-name drug companies and generic drug manufacturers from "gaming" the system to keep the competition off the market. (Bioworld Today)

The race between Transkaryotic Therapies Inc. and Genzyme General to win regulatory approval plus orphan drug designation for their respective Fabry's disease biologics evolved late Wednesday when Transkaryotic said the FDA expressed concerns about some of its data. (BioWorld Today)

The race between Transkaryotic Therapies Inc. and Genzyme General to win regulatory approval plus orphan drug designation for their respective Fabry's disease biologics evolved late Wednesday when Transkaryotic said the FDA expressed concerns about some of its data. (BioWorld Today)